Clinical pattern of zileuton-associated liver injury: Results of a 12-month study in patients with chronic asthma

Drug Safety

Volumn 30, Issue 9, 2007, Pages 805-815

  Watkins, Paul B ^a   Dube, Louise M ^b   Walton Bowen, Karen ^c   Cameron, Christopher M ^d   Kasten, Linda E ^d  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b Pleiades Consultation Inc   (United States)

^c Critical Therapeutics Inc   (United States)

^d PROMETRIKA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALBUTAMOL; SALMETEROL; ZILEUTON;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; LIVER FUNCTION TEST; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT CARE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; ASTHMA; CHRONIC DISEASE; FEMALE; HEPATITIS, TOXIC; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; LIVER FUNCTION TESTS; MALE; PROSPECTIVE STUDIES;

EID: 34548311561     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730090-00006     Document Type: Article

References (22)

1. Weinblatt M, Kremer J, Helfgott S, et al. A 5-lipoxygenase inhibitor in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 1990; 33: S152
2. Stenson WP, Lauritsen LS, Laursen J, et al. A clinical trial of zileuton, a specific inhibitor of 5-lipoxygenase in ulcerative [abstract]. Gastroenterology 1991; 100: A253
3. Abbott Laboratories. Product label. Zyflo® [zileuton tablets]. Revised 2005 Nov
4. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor in patients with asthma: a randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275: 931-6
5. Liu MC, Dube LM, Lancaster J, et al. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a six-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859-71
6. Data on file, Zileuton NDA Safety Update 1. Critical Therapeutics, Inc., 1994 Nov
7. Maddrey WC. Drug-induced hepatotoxicity 2005. J Clin Gastroenterol 2005; 39 Suppl. 2: S83-9
8. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nature Rev Drug Discov 2005; 4: 489-99
9. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Eng J Med 2006; 354: 731-9
10. Senior JR. In: Kaplowitz N, DeLeve L, editors. Drug-induced liver diseases. New York: Marcel Dekker, 2003:739-54
11. Maddrey WC. Clinical presentation of drug-induced liver injury. In: Kaplowitz N, DeLeve L, editors. Drug-induced liver diseases. New York: Marcel Dekker, 2003: 227-42
12. Lazarus SC, Lee T, Kemp JP, et al. Safety and clinical efficacy of zileuton in patients with chronic asthma. Am J Man Care 198; 4: 841-8
13. Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272-6
14. PhRMA/FDA/AASLD drug-induced hepatotoxicity white paper postmarketing considerations [online]. Available from URL: http://www.fda.gov/cder/livertox/ postmarket.pdf [Accessed 2007 Aug 6]
15. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33: 1-5
16. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24: 483-90
17. Lee WM. Drug-induced hepatotoxicity. N Eng J Med 2003; 349: 474-85
18. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32: 77-88
19. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38: S44-8
20. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd Ed. Philadelphia (PA): Lippincott Williams and Wilkins, 1999: 133
21. Lewis JH. 'Hy's Law,' the 'Rezulin Rule,' and other predictors of drug-induced hepatotoxicity: putting risk into perspective. Pharmacoepidemiol Drug Saf 2006; 15: 221-9
22. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-9